Mark Connor

How opioids inhibit GABA-mediated neurotransmission

Christopher W. Vaughan, Susan Ingram, Mark Connor et al. · Nature · 1997 · 506 citations

Life Sciences, Neuroscience, Pharmacology +12

Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists

Alexander Gillis, Arisbel B. Gondin, Andrea Kliewer et al. · Science Signaling · 2020 · 365 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity

Marjolein Soethoudt, Uwe Grether, Jürgen Fingerle et al. · Nature Communications · 2017 · 351 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Pharmacology of Valinate and<i>tert</i>-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues

Samuel D. Banister, Mitchell Longworth, Richard C. Kevin et al. · ACS Chemical Neuroscience · 2016 · 247 citations

Pharmacy, Medicinal Chemistry, Pharmacology +13

Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA

Samuel D. Banister, Michael Moir, Jordyn Stuart et al. · ACS Chemical Neuroscience · 2015 · 241 citations

Pharmacy, Medicinal Chemistry, Pharmacology +12